Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC).

Full DD Report for CYCC

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYCC)

Cyclacel Pharmaceuticals to Release Third Quarter 2018 Financial Results
BERKELEY HEIGHTS, N.J., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results on Mond...
Source: GlobeNewswire
Date: November, 06 2018 07:00
Cyclacel Pharmaceuticals (CYCC) Presents At DAWSON JAMES 4th Annual Small Cap Growth Conference - Slideshow
The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: October, 31 2018 18:08
Report: Exploring Fundamental Drivers Behind Invitae, Aerie Pharmaceuticals, Gevo, Global Medical REIT, Cyclacel Pharmaceuticals, and Toll Brothers - New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Invitae Corporation (NYSE:NVTA), Aerie Pharmaceuticals, Inc. (NASDAQ:A...
Source: GlobeNewswire
Date: October, 25 2018 08:30
Premarket Gainers as of 9:05 am (09/05/2018)
PRQR +66%  on positive interim results from Phase 1/2 clinical trial of QR-110 in LCA10 patients. More news on: ProQR Therapeutics, Cronos Group, Inc., Nevsun Resources Ltd., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 05 2018 09:21
Factors of Influence in 2018, Key Indicators and Opportunity within Aerie Pharmaceuticals, BioScrip, Celsion, Primoris Services, Cyclacel Pharmaceuticals, and Barnes Group - New Research Emphasizes Economic Growth
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), BioScrip, Inc. (NASDAQ:BIOS),...
Source: GlobeNewswire
Date: September, 05 2018 07:30
Cyclacel Pharmaceuticals to Present at the 20th Annual H.C. Wainwright Global Investment Conference
BERKELEY HEIGHTS, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, announces that the Company will present at the 20th Annual...
Source: GlobeNewswire
Date: August, 29 2018 07:00
Investor Expectations to Drive Momentum within Global Medical REIT, Cyclacel Pharmaceuticals, Super Micro Computer, Kelly Services, Invitae, and ScanSource - Discovering Underlying Factors of Influence
NEW YORK, Aug. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Global Medical REIT Inc. (NYSE:GMRE), Cyclacel Pharmaceuticals, Inc. (NAS...
Source: GlobeNewswire
Date: August, 16 2018 08:15
Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2018 Results - Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2018 Results Earnings Conference Call August 09, 2018, 4:30 pm ET Executives Alexander Fudukidis - Investor Relations, Vice President at Russo Partners, LLC Spiro Rombotis - President, Chief Executive Officer Paul McBarron - Executive Vice...
Source: SeekingAlpha
Date: August, 09 2018 20:01
Cyclacel Pharmaceuticals misses by $0.04
Cyclacel Pharmaceuticals (NASDAQ: CYCC ): Q2 EPS of -$0.16 misses by $0.04 . More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 09 2018 16:38
Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today reported financial results and business highlights ...
Source: GlobeNewswire
Date: August, 09 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-081.551.531.601.461116,493
2018-05-171.3711.391.411.3767,059
2017-02-035.085.205.265.0234,909
2017-02-025.09994.985.144.82518,600
2017-02-014.695.125.144.6832,726

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-108,83933,01726.7711Cover
2018-12-0721,91835,04362.5460Short
2018-12-069,96432,19130.9528Cover
2018-12-0447,79394,66250.4881Short
2018-12-037,85816,82646.7015Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYCC.


About Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Logo for Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Not available

 

Contact Information

 

 

Current Management

  • Spiro Rombotis / President, CEO
  • Paul McBarron / COO
  • Corey Sohmer / IR

Current Share Structure

  • Market Cap: $16,556,477 - 05/15/2018
  • Issue and Outstanding: 11,997,447 - 03/27/2018

 


Recent Filings from (NASDAQ: CYCC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 12 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 12 2017

 

 


Daily Technical Chart for (NASDAQ: CYCC)

Daily Technical Chart for (NASDAQ: CYCC)


Stay tuned for daily updates and more on (NASDAQ: CYCC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYCC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYCC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CYCC and does not buy, sell, or trade any shares of CYCC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/